Assessment of physical stability of an antibody drug conjugate by higher order structure analysis: Impact of thiol-maleimide chemistry

Pharmaceutical Research

Volumn 31, Issue 7, 2014, Pages 1710-1723

  Guo, Jianxin ^a   Kumar, Sandeep ^a   Prashad, Amarnauth ^a   Starkey, Jason ^a   Singh, Satish K ^a  

^a PFIZER INC   (United States)

Author keywords

antibody drug conjugates; fluorescent dyes; molecular model; physical stability; thiol maleimide chemistry

Indexed keywords

ANTIBODY CONJUGATE; ANTIBODY DRUG CONJUGATE; MALEIMIDE; MONOCLONAL ANTIBODY; SELENIUM; SOLVENT; THIOL; UNCLASSIFIED DRUG; IMMUNOGLOBULIN G; MALEIMIDE DERIVATIVE; PROTEIN AGGREGATE; THIOL DERIVATIVE;

ANTIBODY STRUCTURE; ARTICLE; CIRCULAR DICHROISM; COLLOID; CONFORMATIONAL TRANSITION; DIFFERENTIAL SCANNING CALORIMETRY; DISULFIDE BOND; DRUG CONFORMATION; DRUG CONJUGATION; DRUG FORMULATION; DRUG STABILITY; DRUG STRUCTURE; FLUORESCENCE SPECTROSCOPY; FLUOROMETRY; GEL PERMEATION CHROMATOGRAPHY; HEAT; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HYDROPHILICITY; HYDROPHOBICITY; MELTING POINT; MOLECULAR MODEL; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; PROTEIN SECONDARY STRUCTURE; PROTEIN TERTIARY STRUCTURE; SOLVENT EFFECT; STRUCTURE ANALYSIS; SURFACE PROPERTY; TEMPERATURE STRESS; TURBIDITY; ULTRAVIOLET SPECTROSCOPY; CHEMICAL STRUCTURE; CHEMISTRY; PROTEIN STABILITY;

ANTIBODIES, MONOCLONAL; DRUG STABILITY; IMMUNOCONJUGATES; IMMUNOGLOBULIN G; MALEIMIDES; MODELS, MOLECULAR; PROTEIN AGGREGATES; PROTEIN STABILITY; PROTEIN STRUCTURE, SECONDARY; PROTEIN STRUCTURE, TERTIARY; SULFHYDRYL COMPOUNDS;

EID: 84904248537     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-013-1274-2     Document Type: Article

References (36)

1. Wu AM, Senter PD. Arming antibodies: prospects and challenges for immunoconjugates. Nat Biotechnol. 2005;23(9):1137-46.
2. Chari RV. Targeted cancer therapy: conferring specificity to cytotoxic drugs. Acc Chem Res. 2008;41(1):98-107.
3. Alley SC, Benjamin DR, Jeffrey SC, Okeley NM, Meyer DL, Sanderson RJ, et al. Contribution of linker stability to the activities of anticancer immunoconjugates. Bioconjug Chem. 2008;19(3):759-65.
4. Baldwin AD, Kiick KL. Tunable degradation of maleimide-thiol adducts in reducing environments. Bioconjug Chem. 2011;22(10):1946-53.
5. Chih HW, Gikanga B, Yang Y, Zhang B. Identification of amino acid residues responsible for the release of free drug from an antibody-drug conjugate utilizing lysine-succinimidyl ester chemistry. J Pharm Sci. 2011;100(7):2518-25.
6. Hamblett KJ, Senter PD, Chace DF, Sun MM, Lenox J, Cerveny CG, et al. Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate. Clin Cancer Res Off J Am Assoc Cancer Res. 2004;10(20):7063-70.
7. Sun MM, Beam KS, Cerveny CG, Hamblett KJ, Blackmore RS, Torgov MY, et al. Reduction-alkylation strategies for the modification of specific monoclonal antibody disulfides. Bioconjug Chem. 2005;16(5):1282-90.
8. Wakankar A, Chen Y, Gokarn Y, Jacobson FS. Analytical methods for physicochemical characterization of antibody drug conjugates. mAbs. 2011;3(2):161-72.
9. Wakankar AA, Feeney MB, Rivera J, Chen Y, Kim M, Sharma VK, et al. Physicochemical stability of the antibody-drug conjugate Trastuzumab-DM1: changes due to modification and conjugation processes. Bioconjug Chem. 2010;21(9):1588-95.
10. Hu L, Olsen C, Maddux N, Joshi SB, Volkin DB, Middaugh CR. Investigation of protein conformational stability employing a multimodal spectrometer. Anal Chem. 2011;83(24):9399-405.
11. Fan H, Ralston J, Dibiase M, Faulkner E, Middaugh CR. Solution behavior of IFN-beta-1a: an empirical phase diagram based approach. J Pharm Sci. 2005;94(9):1893-911.
12. Kayser V, Chennamsetty N, Voynov V, Helk B, Trout BL. Conformational stability and aggregation of therapeutic monoclonal antibodies studied with ANS and Thioflavin T binding. mAbs. 2011;3(4):408-11.
13. Ramsey JD, Gill ML, Kamerzell TJ, Price ES, Joshi SB, Bishop SM, et al. Using empirical phase diagrams to understand the role of intramolecular dynamics in immunoglobulin G stability. J Pharm Sci. 2009;98(7):2432-47.
14. Guo J, Harn N, Robbins A, Dougherty R, Middaugh CR. Stability of helix-rich proteins at high concentrations. Biochemistry. 2006;45(28):8686-96.
15. Saphire EO, Parren PW, Pantophlet R, Zwick MB, Morris GM, Rudd PM, et al. Crystal structure of a neutralizing human IGG against HIV-1: a template for vaccine design. Science. 2001;293(5532):1155-9.
16. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, et al. The Protein Data Bank. Nucleic Acids Res. 2000;28(1):235-42.
17. Franey H, Brych SR, Kolvenbach CG, Rajan RS. Increased aggregation propensity of IgG2 subclass over IgG1: role of conformational changes and covalent character in isolated aggregates. Protein Sci Publ Protein Soc. 2010;19(9):1601-15.
18. Agrawal NJ, Kumar S, Wang X, Helk B, Singh SK, Trout BL. Aggregation in protein-based biotherapeutics: computational studies and tools to identify aggregation-prone regions. J Pharm Sci. 2011;100(12):5081-95.
19. Sreerama N, Manning MC, Powers ME, Zhang JX, Goldenberg DP, Woody RW. Tyrosine, phenylalanine, and disulfide contributions to the circular dichroism of proteins: circular dichroism spectra of wild-type and mutant bovine pancreatic trypsin inhibitor. Biochemistry. 1999;38(33):10814-22.
20. Kueltzo LA, Ersoy B, Ralston JP, Middaugh CR. Derivative absorbance spectroscopy and protein phase diagrams as tools for comprehensive protein characterization: a bGCSF case study. J Pharm Sci. 2003;92(9):1805-20.
21. Nonoyama A, Laurence JS, Garriques L, Qi H, Le T, Middaugh CR. A biophysical characterization of the peptide drug pramlintide (AC137) using empirical phase diagrams. J Pharm Sci. 2008;97(7):2552-67.
22. He F, Hogan S, Latypov RF, Narhi LO, Razinkov VI. High throughput thermostability screening of monoclonal antibody formulations. J Pharm Sci. 2010;99(4):1707-20.
23. Haidekker MA, Brady TP, Lichlyter D, Theodorakis EA. Effects of solvent polarity and solvent viscosity on the fluorescent properties of molecular rotors and related probes. Bioorg Chem. 2005;33(6):415-25.
24. Haidekker MA, Theodorakis EA. Environment-sensitive behavior of fluorescent molecular rotors. J Biol Eng. 2010;4:11.
25. Hawe A, Filipe V, Jiskoot W. Fluorescent molecular rotors as dyes to characterize polysorbate-containing IgG formulations. Pharm Res. 2010;27(2):314-26.
26. Kung CE, Reed JK. Fluorescent molecular rotors: a new class of probes for tubulin structure and assembly. Biochemistry. 1989;28(16):6678-86.
27. Lindgren M, Sorgjerd K, Hammarstrom P. Detection and characterization of aggregates, prefibrillar amyloidogenic oligomers, and protofibrils using fluorescence spectroscopy. Biophys J. 2005;88(6):4200-12.
28. Nelson R, Sawaya MR, Balbirnie M, Madsen AO, Riekel C, Grothe R, et al. Structure of the cross-beta spine of amyloid-like fibrils. Nature. 2005;435(7043):773-8.
29. Sawaya MR, Sambashivan S, Nelson R, Ivanova MI, Sievers SA, Apostol MI, et al. Atomic structures of amyloid cross-beta spines reveal varied steric zippers. Nature. 2007;447(7143):453-7.
30. Brummitt RK, Nesta DP, Chang L, Kroetsch AM, Roberts CJ. Nonnative aggregation of an IgG1 antibody in acidic conditions, part 2: nucleation and growth kinetics with competing growth mechanisms. J Pharm Sci. 2011;100(6):2104-19.
31. Mason BD, Zhang L, Remmele Jr RL, Zhang J. Opalescence of an IgG2 monoclonal antibody solution as it relates to liquid-liquid phase separation. J Pharm Sci. 2011;100(11):4587-96.
32. Ionescu RM, Vlasak J, Price C, Kirchmeier M. Contribution of variable domains to the stability of humanized IgG1 monoclonal antibodies. J Pharm Sci. 2008;97(4):1414-26.
33. Buck PM, Kumar S, Wang X, Agrawal NJ, Trout BL, Singh SK. Computational methods to predict therapeutic protein aggregation. Methods Mol Biol. 2012;899:425-51.
34. Sahin E, Grillo AO, Perkins MD, Roberts CJ. Comparative effects of pH and ionic strength on protein-protein interactions, unfolding, and aggregation for IgG1 antibodies. J Pharm Sci. 2010;99(12):4830-48.
35. Chi EY, Krishnan S, Randolph TW, Carpenter JF. Physical stability of proteins in aqueous solution: mechanism and driving forces in nonnative protein aggregation. Pharm Res. 2003;20(9):1325-36.
36. Lee HJ, McAuley A, Schilke KF, McGuire J. Molecular origins of surfactant-mediated stabilization of protein drugs. Adv Drug Deliv Rev. 2011;63(13):1160-71.